These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8210922)

  • 1. Pharmacokinetics of sustained-release etodolac.
    Benet LZ
    Rheumatol Int; 1993; 13(2 Suppl):S3-5. PubMed ID: 8210922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis.
    Dreiser RL
    Rheumatol Int; 1993; 13(2 Suppl):S13-8. PubMed ID: 8210919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety profile of sustained-release etodolac.
    Schattenkirchner M
    Rheumatol Int; 1993; 13(2 Suppl):S31-5. PubMed ID: 8210923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic modeling and simulation of etodolac following single oral administration in dogs.
    Baek IH
    Xenobiotica; 2019 Aug; 49(8):981-986. PubMed ID: 30216103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The stereoselective pharmacokinetics of etodolac in young and elderly subjects, and after cholecystectomy.
    Brocks DR; Jamali F; Russell AS; Skeith KJ
    J Clin Pharmacol; 1992 Nov; 32(11):982-9. PubMed ID: 1474171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etodolac clinical pharmacokinetics.
    Brocks DR; Jamali F
    Clin Pharmacokinet; 1994 Apr; 26(4):259-74. PubMed ID: 8013160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profile of etodolac in special populations.
    Benet LZ
    Eur J Rheumatol Inflamm; 1994; 14(1):15-8. PubMed ID: 7744123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery.
    Boni J; Korth-Bradley J; McGoldrick K; Appel A; Cooper S
    J Clin Pharmacol; 1999 Jul; 39(7):729-37. PubMed ID: 10392328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chiral bioequivalence: effect of absorption rate on racemic etodolac.
    Boni JR; Korth-Bradley JM; Richards LS; Chiang ST; Hicks DR; Benet LZ
    Clin Pharmacokinet; 2000 Dec; 39(6):459-69. PubMed ID: 11192477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee.
    Perpignano G; Bogliolo A; Puccetti L
    Int J Clin Pharmacol Res; 1994; 14(5-6):203-16. PubMed ID: 7672877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food.
    Kim TE; Kim JR; Jung JA; Kim MJ; Lee SY; Ko JW; Jung WT; Choi YW; Lee HJ; Kim SH; Huh W
    J Clin Pharm Ther; 2014 Apr; 39(2):192-5. PubMed ID: 24325365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of etodolac SR and naproxen on gastro-intestinal blood loss.
    Leese P
    Curr Med Res Opin; 1992; 13(1):13-20. PubMed ID: 1468240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison of etodolac SR and diclofenac SR in the treatment of patients with degenerative joint disease of the knee.
    Khan FM; Williams PI
    Curr Med Res Opin; 1992; 13(1):1-12. PubMed ID: 1468239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of etodolac in the horse following oral and intravenous administration.
    Davis JL; Papich MG; Morton AJ; Gayle J; Blikslager AT; Campbell NB
    J Vet Pharmacol Ther; 2007 Feb; 30(1):43-8. PubMed ID: 17217400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.
    Modi NB; Lindemulder B; Gupta SK
    J Clin Pharmacol; 2000 Apr; 40(4):379-88. PubMed ID: 10761165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation.
    Barakat NS
    J Pharm Pharmacol; 2010 Feb; 62(2):173-80. PubMed ID: 20487196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation, Characterization and In Vitro / In Vivo Evaluation of Oral Time-Controlled Release Etodolac Pellets.
    Zhang X; Li Q; Ye M; Zhao Z; Sun J; Yang X; Pan W
    AAPS PharmSciTech; 2018 Feb; 19(2):610-620. PubMed ID: 28917009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional and extended-release etodolac for postsurgical dental pain.
    Hersh EV; Levin LM; Cooper SA; Reynolds D; Gallegos LT; McGoldrick K; Appel A
    Clin Ther; 1999 Aug; 21(8):1333-42. PubMed ID: 10485505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and bioequivalence of two formulations of etodolac (tablets and suppositories).
    Molina-Martinez IT; Herrero R; Gutiérrez JA; Iglesias JM; Fábregas JL; Martinez-Tobed A; Cadorniga R
    J Pharm Sci; 1993 Feb; 82(2):211-3. PubMed ID: 8445537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee.
    Porzio F
    Rheumatol Int; 1993; 13(2 Suppl):S19-24. PubMed ID: 8210920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.